RIDGEFIELD, Conn. and
INDIANAPOLIS, June 28, 2016 /PRNewswire/ -- A U.S. Food and
Drug Administration (FDA) Advisory Committee today voted 12-11 that
substantial evidence exists to establish that Jardiance®
(empagliflozin) reduces cardiovascular (CV) death in adults with
type 2 diabetes (T2D) and established CV disease. JARDIANCE, which
is marketed by Boehringer Ingelheim and Eli Lilly and Company
(NYSE: LLY), is the only oral T2D medicine shown in a clinical
trial to reduce the risk of CV death.
"Today's robust discussion and resulting vote are
important as we look to gain approval of a new indication for
JARDIANCE as the first type 2 diabetes treatment to provide a
cardiovascular benefit," said Thomas Seck, M.D., vice president,
Clinical Development and Medical Affairs – Metabolism, Boehringer
Ingelheim Pharmaceutical, Inc. "We look forward to continuing to
work with the FDA in our ongoing efforts to provide options that
help reduce the risk of cardiovascular death in adults with type 2
diabetes and established cardiovascular disease."
The recommendation was made by the Endocrinologic and Metabolic
Drugs Advisory Committee based on data from the landmark EMPA-REG
OUTCOME® trial, which found that JARDIANCE significantly
reduced the risk of the combined endpoint of CV death, non-fatal
heart attack or non-fatal stroke by 14 percent when added to
standard of care in adults with T2D and established CV disease. The
primary finding was driven by a 38 percent reduction in CV death,
with no significant difference in the risk of non-fatal heart
attack or non-fatal stroke. The overall safety profile of JARDIANCE
was consistent with that of previous trials.
"Despite significant advances in the prevention and treatment of
cardiovascular disease over the past several decades, more than
half of adults with type 2 diabetes worldwide still die due to
cardiovascular causes," said Jeff
Emmick, M.D., Ph.D., vice president, product development,
Lilly Diabetes. "The cardioprotective profile of JARDIANCE
could provide an additional option to physicians to reduce the risk
of cardiovascular death in their patients with type 2
diabetes."
About the EMPA-REG OUTCOME Trial
(NCT01131676)
EMPA-REG OUTCOME was a long-term, multicenter,
randomized, double-blind, placebo-controlled trial of more than
7,000 patients, from 42 countries, with T2D and established CV
disease.
The study assessed the effect of JARDIANCE (10 mg or 25 mg once
daily) added to standard of care compared with placebo added to
standard of care. Standard of care was comprised of
glucose-lowering agents and CV drugs (including for blood pressure
and cholesterol). The primary endpoint was defined as time to first
occurrence of CV death, non-fatal heart attack or non-fatal
stroke.
Over a median of 3.1 years, JARDIANCE significantly reduced the
risk of CV death, non-fatal heart attack or non-fatal stroke by 14
percent versus placebo. Risk of CV death was reduced by 38 percent,
with no significant difference in the risk of non-fatal heart
attack or non-fatal stroke.
The overall safety profile of JARDIANCE in the EMPA-REG OUTCOME
trial was consistent with that of previous trials.
About Diabetes and Cardiovascular Disease
Approximately 29 million Americans and an estimated 415 million
people worldwide have diabetes, and nearly 28 percent of Americans
with diabetes—totaling 8 million people—are undiagnosed. In the
U.S., approximately 12 percent of those aged 20 and older have
diabetes. T2D is the most common type, accounting for an estimated
90 to 95 percent of all diagnosed adult diabetes cases in the U.S.
Diabetes is a chronic condition that occurs when the body either
does not properly produce, or use, the hormone insulin.
Due to the complications associated with diabetes, such as high
blood sugar, high blood pressure and obesity, CV disease is a major
complication and the leading cause of death associated with
diabetes. People with diabetes are two to four times more
likely to develop CV disease than people without diabetes. In
2015, diabetes caused 5 million deaths worldwide, with CV disease
as the leading cause. Approximately 50 percent of deaths in people
with T2D worldwide are caused by CV disease. In the U.S., health
care costs for managing CV conditions in patients with diabetes
totaled more than $23 billion dollars
in 2012.
What is JARDIANCE?
JARDIANCE is a prescription medicine used along with diet and
exercise to lower blood sugar in adults with type 2 diabetes.
JARDIANCE is not for people with type 1 diabetes or for people with
diabetic ketoacidosis (increased ketones in the blood or
urine).
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
JARDIANCE?
JARDIANCE can cause serious side effects, including:
- Dehydration. JARDIANCE can cause some people to
have dehydration (the loss of body water and salt). Dehydration may
cause you to feel dizzy, faint, light-headed, or weak, especially
when you stand up.
You may be at a higher risk of dehydration if you:
- have low blood pressure
- take medicines to lower your blood pressure, including water
pills (diuretics)
- are on a low salt diet
- have kidney problems
- are 65 years of age or older.
- Ketoacidosis (increased ketones in your blood or urine).
Ketoacidosis can be life threatening and may need to be treated in
the hospital. Ketoacidosis occurs in people with type 1 diabetes
and can also occur in people with type 2 diabetes taking JARDIANCE,
even if blood sugar is less than 250 mg/dL. Stop taking
JARDIANCE and call your doctor right away if you get any of the
following symptoms, and if possible, check for ketones in your
urine:
-
nausea
- vomiting
- stomach-area (abdominal) pain
- tiredness
- trouble breathing
- Serious urinary tract infections. Serious urinary tract
infections can occur in people taking JARDIANCE and may lead to
hospitalization. Tell your doctor if you have symptoms of a urinary
tract infection such as a burning feeling when passing urine, a
need to urinate often or right away, pain in the lower part of your
stomach or pelvis, or blood in the urine. Sometimes people also may
have a fever, back pain, nausea or vomiting.
- Vaginal yeast infection. Women who take JARDIANCE may
get vaginal yeast infections. Talk to your doctor if you experience
vaginal odor, white or yellowish vaginal discharge (discharge may
be lumpy or look like cottage cheese), and/or vaginal itching.
- Yeast infection of the penis. Men who take JARDIANCE may
get a yeast infection of the skin around the penis, especially
uncircumcised males and those with chronic infections. Talk
to your doctor if you experience redness, itching or swelling of
the penis, rash of the penis, foul smelling discharge from the
penis, and /or pain in the skin around penis.
Who should not take JARDIANCE?
Do not take JARDIANCE if you are allergic to
empagliflozin or any of the ingredients in JARDIANCE. Symptoms of
serious allergic reactions to JARDIANCE may include:
- skin rash
- raised red patches on your skin (hives)
- swelling of the face, lips, tongue, and throat that may cause
difficulty breathing or swallowing.
If you have any of these symptoms, stop taking JARDIANCE and
contact your doctor or go to the nearest emergency room right
away.
Do not take JARDIANCE if you have severe kidney problems
or are on dialysis.
What should I tell my doctor before using JARDIANCE?
Tell your doctor if you:
- have kidney problems. Your doctor may do blood tests to check
your kidneys before and during your treatment with JARDIANCE
- have liver problems
- have a history of urinary tract infections or problems with
urination
- are going to have surgery
- are eating less due to illness, surgery, or a change in your
diet
- have or have had problems with your pancreas, including
pancreatitis or surgery on your pancreas
- drink alcohol very often, or drink a lot of alcohol in the
short term ("binge" drinking)
- have any other medical conditions
- are pregnant or planning to become pregnant. It is unknown if
JARDIANCE will harm your unborn baby
- are breastfeeding, or plan to breastfeed. It is unknown if
JARDIANCE passes into your breast milk.
Tell your doctor about all the medicines you take
including prescription and over-the-counter medicines, vitamins,
and herbal supplements. Especially tell your doctor if you take
water pills (diuretics) or medicines that can lower your blood
sugar such as insulin.
What are other possible side effects of JARDIANCE?
- Low blood sugar (hypoglycemia): if you take JARDIANCE
with another medicine that can cause low blood sugar, such as
sulfonylurea or insulin, your risk of low blood sugar is higher.
The dose of your sulfonylurea or insulin may need to be lowered.
Symptoms of low blood sugar may include:
- Headache
- Drowsiness
- Weakness
- Dizziness
- Confusion
- Irritability
- Hunger
- Fast heart beat
- Sweating
- Shaking or feeling jittery
- Kidney Problems, especially in people 75 years of age or
older and people who already have kidney problems
- Increased fats in your blood (cholesterol).
The most common side effects of JARDIANCE include urinary
tract infections, and yeast infections in females.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
For more information, please see full Prescribing Information,
including Patient Information.
JAR CONS ISI 12.8.15
Boehringer Ingelheim and Eli Lilly and Company
In
January 2011, Boehringer Ingelheim
and Eli Lilly and Company announced an alliance in diabetes that
centers on compounds representing several of the largest diabetes
treatment classes. This alliance leverages the strengths of two of
the world's leading pharmaceutical companies. By joining forces,
the companies demonstrate commitment in the care of patients with
diabetes and stand together to focus on patient needs. Find out
more about the alliance at www.boehringer-ingelheim.com or
www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary
of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with
145 affiliates and more than 47,000 employees. Since its founding
in 1885, the family-owned company has been committed to
researching, developing, manufacturing and marketing novel
treatments for human and veterinary medicine.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and families.
Our employees create and engage in programs that strengthen our
communities. To learn more about how we make more health for more
people, visit our Corporate Social Responsibility Report.
In 2015, Boehringer Ingelheim achieved net sales of about
$15.8 billion dollars (14.8 billion euros). R&D expenditure
corresponds to 20.3 percent of its net sales.
For more information please visit
www.us.boehringer-ingelheim.com, or follow us on Twitter
@BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a broad and
growing product portfolio and a continued determination to provide
real solutions—from medicines to support programs and more—we
strive to make life better for all those affected by diabetes
around the world. For more information, visit
www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about JARDIANCE as a treatment of adults with
type 2 diabetes and established CV disease, and reflects Lilly's
current belief. However, as with any pharmaceutical product,
there are substantial risks and uncertainties in the process of
development and commercialization. Among other things, there can be
no guarantee that future study results will be consistent with the
results to date or that JARDIANCE will receive additional
regulatory approvals. For further discussion of these and
other risks and uncertainties, see Lilly's most recent Form 10-K
and Form 10-Q filings with the United States Securities and
Exchange Commission. Except as required by law, Lilly undertakes no
duty to update forward-looking statements to reflect events after
the date of this release.
Jardiance® and EMPA-REG OUTCOME® are
registered trademarks of Boehringer Ingelheim.
P-LLY
PC-JAR-0016-PR
CONTACT:
Jennifer
Forsyth
Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: jennifer.forsyth@boehringer-ingelheim.com
Phone: (203) 791-5889
Molly
McCully
Communications Manager
Lilly Diabetes
Email: mccully_molly@lilly.com
Phone: (317) 478-5423
Logo -
http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Logo -
http://photos.prnewswire.com/prnh/20110825/DE57898LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/fda-advisory-committee-recommends-approval-of-jardiance-empagliflozin-for-cardiovascular-indication-in-12-11-vote-300291733.html
SOURCE Eli Lilly and Company; Boehringer Ingelheim